Page 4 - Bruce Strober News Today

Positive data represents a boost for patients with moderate to severe plaque psoriasis - News - PharmaTimes

WEDNESDAY, July 13, 2022 (HealthDay News) -- Four in 10 plaque psoriasis patients achieve complete disease clearance with tapinarof cream, 1 percent, according to a study published online June 26 in the Journal of the American Academy of Dermatology. Bruce Strober, M.D., Ph.D., from Yale University in New Haven, Connecticut, and colleagues assessed the long-term

Press release content from PR Newswire. The AP news staff was not involved in its creation.

An important external recognition of the potential of SINTAX medicines. We believe this puts EDP1815 and SINTAX medicines in a strong position as we move closer to realizing our vision to improve... | March 24, 2022

Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis - read this article along with other careers information, tips and advice on BioSpace

-18/30 patients maintained a PASI-50 or greater response at 24 weeks post-treatment- -9/20 patients experienced a deepening of response from PASI-50 to at least PASI-75 during post-treatment period- -No flare

Palmoplantar psoriasis is a type of psoriasis on your palms and soles of your feet that can be especially difficult to treat. But there are ways to get this challenging condition under control. The post 18 Things You Should Know About Palmoplantar Psoriasis appeared first on The Healthy.

Ear psoriasis can impair your hearing if it spreads to your ear canal. Learn about its symptoms, treatments, and how to prevent hearing loss. The post 10 Ways to Deal With Psoriasis in Your Ears appeared first on The Healthy.

Dermavant Sciences: Dermavant Announces Tapinarof Data Presentations at the AAD VMX 2021 Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that two abstracts from Dermavants two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, will be presented during the upcoming American Academy of Dermatology Virtual Meeting Experienc...

Dermavant Sciences: Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that an abstract containing interim analysis data from Dermavants PSOARING 3 long-term, open-label safety study for tapinarof for the treatment of psoriasis in adults will be presented in poster format during the upc...